BioCentury | Mar 17, 2016
Translation in Brief

Trans-hemispheric express

A University of North Carolina at Chapel Hill team has made human neural progenitor cells directly from fibroblasts and shown the transdifferentiated cells can serve as tumor-homing carriers of chemotherapeutic agents for brain cancer. While...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Cancer INDICATION: Brain cancer Mouse studies suggest skin fibroblast-derived neural progenitor cells that secrete a soluble form of TRAIL could help treat glioblastoma. In a xenograft mouse model of glioblastoma, tumor site transplants of neural...
BioCentury | Jul 9, 2007
Clinical News

Lomucin talniflumate: Development discontinued

...exclusive license to develop and commercialize Lomucin in the U.S., EU and Japan from Bago. Bago Group...
BioCentury | Jul 6, 2007
Company News

Genaera ends Lomucin, squalamine trials

...which was recently acquired by AstraZeneca (LSE:AZN; AZN). GENR has rights to Lomucin from Laboratorios Bago...
BioCentury | Sep 26, 2005
Clinical News

Lomucin: Phase II started

...double-blind, placebo-controlled, European Phase II trial in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn. Bago Group...
BioCentury | Apr 25, 2005
Clinical News

Lomucin: Phase II start

...European Phase II trial of Lomucin in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn. Bago Group...
BioCentury | Apr 19, 2005
Clinical News

Genaera starts Lomucin pivotal Phase II

...the second half of 2007. The calcium-activated chloride channel (gob-5) antagonist is partnered with Laboratories Bago...
Items per page:
1 - 7 of 7
BioCentury | Mar 17, 2016
Translation in Brief

Trans-hemispheric express

A University of North Carolina at Chapel Hill team has made human neural progenitor cells directly from fibroblasts and shown the transdifferentiated cells can serve as tumor-homing carriers of chemotherapeutic agents for brain cancer. While...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Cancer INDICATION: Brain cancer Mouse studies suggest skin fibroblast-derived neural progenitor cells that secrete a soluble form of TRAIL could help treat glioblastoma. In a xenograft mouse model of glioblastoma, tumor site transplants of neural...
BioCentury | Jul 9, 2007
Clinical News

Lomucin talniflumate: Development discontinued

...exclusive license to develop and commercialize Lomucin in the U.S., EU and Japan from Bago. Bago Group...
BioCentury | Jul 6, 2007
Company News

Genaera ends Lomucin, squalamine trials

...which was recently acquired by AstraZeneca (LSE:AZN; AZN). GENR has rights to Lomucin from Laboratorios Bago...
BioCentury | Sep 26, 2005
Clinical News

Lomucin: Phase II started

...double-blind, placebo-controlled, European Phase II trial in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn. Bago Group...
BioCentury | Apr 25, 2005
Clinical News

Lomucin: Phase II start

...European Phase II trial of Lomucin in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn. Bago Group...
BioCentury | Apr 19, 2005
Clinical News

Genaera starts Lomucin pivotal Phase II

...the second half of 2007. The calcium-activated chloride channel (gob-5) antagonist is partnered with Laboratories Bago...
Items per page:
1 - 7 of 7